Contrast-induced Nephropathy Clinical Trial
Official title:
Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)
A randomized, placebo-controlled, double-blind clinical trial of effect of allopurinol or febuxostat to prevent contrast induced acute kidney injury (CI-AKI)
Eligible patients (patients with glomerular filtration rate < 60 ml/min or high riks patients
based on Mehran score) that will be undergoing cardiac catheterization/intervention randomly
assigned to receive allopurinol 300 mg or febuxostat 80 mg 12 hours before and 12 after 1
exposure of radiocontrast and IV hydration (normal saline 1 ml/kg/hr 12 pre and post
radiocontrast exposure) or placebo and hydration.
Exclusion criteria: patients under treatment with allopurinol or febuxostat in the previous
seven days, known allergy to allopurinol or febuxostat, patients on renal replacement therapy
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04877847 -
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
|
N/A | |
Recruiting |
NCT02088502 -
Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy
|
Phase 2/Phase 3 | |
Completed |
NCT03329443 -
The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography
|
Phase 2 | |
Recruiting |
NCT04864847 -
Clinical Validation of the RENISCHEM L-FABP POC Assay
|
||
Completed |
NCT03627130 -
The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy
|
Phase 2 | |
Active, not recruiting |
NCT03736018 -
Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients
|
N/A | |
Withdrawn |
NCT04598516 -
Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
|
||
Withdrawn |
NCT04603261 -
Time to Excretion of Contrast, a Maastricht Prospective Observational Study
|
||
Recruiting |
NCT03755700 -
Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization
|
Phase 3 | |
Active, not recruiting |
NCT04606056 -
Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans
|
||
Terminated |
NCT02440646 -
Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
|
||
Completed |
NCT00175227 -
Prevention of Contrast-Induced Nephropathy
|
N/A | |
Completed |
NCT04014153 -
CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?
|
||
Withdrawn |
NCT04597892 -
Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast
|
||
Completed |
NCT03305874 -
Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
|
||
Not yet recruiting |
NCT01871792 -
Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT06429345 -
Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
|
Phase 4 | |
Recruiting |
NCT05271448 -
Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography
|
N/A | |
Withdrawn |
NCT03806725 -
Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography
|
||
Completed |
NCT04163250 -
Use of Urinary Cell-Cycle Arrest Biomarkers in Contrast-Associated Nephropathy After Coronary Angiography
|